Mission: To support research and development of, and education in, the basic and clinical sciences for the prevention, detection, diagnosis, and treatment of cancer.
Programs: Melanoma research: as one of the largest melanoma centers in the u. S. , the institute conducts landmark research to identify new or recurring melanoma at its earliest stages, predict and monitor the response to systemic treatments, and develop active and passive immunotherapies for surgical and non-surgical patients.
molecular oncology: the key focus of the department of molecular oncology is the development and application of molecular/genetic biomarkers for the diagnosis, prognosis and prediction of treatment response of solid tumors. Emphasis of studies are of the skin (melanoma), breast, and gastrointestinal tract. The department has developed multiple platforms to assess rna and dna of different types of tissues and cancers to improve diagnosis, prognosis and prediction of treatment response and has over 12 years of experience in the field and is continually improving approaches to translational quantitative oncology.
translational immunology: studying populations of patients with enhanced immunity to melanocytes (the autoimmune disease vitiligo) and examining archived specimens of tumor tissue. Using these translational tools to identify key pathways of the immune response to melanoma may provide insights to fighting cancer in general.
Professional with expertise in this field
Predator of in-kind fund donations. A plan B for failed cancer vax projects. Was and is fabricated research on the level of 3/5. Only ultra wealthy benefit, not general public. Average patient mortality high. Not true transparency in practice. Falsely catered past and present foundations. Only strong intangible is brand name.